Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

H
H.A. Bemelmans, Marc

Department of Surgery, Maastricht University Medical Center+, Maastricht
(P 361) WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION: A SINGLE-CENTER RETROSPECTIVE ANALYSIS
Marc H.A. Bemelmans
Favorite
Hårklau, Lisbeth

Oslo University Hospital
(P 40) PEGYLATED LIPOSOMAL DOXORUBICIN IN SYMPTOMATIC DESMOID TUMOR
Lisbeth Hårklau
Favorite
Haarberg, Sasha

Washington University School of Medicine
(P 81) OUTCOMES DATA FOR OSTEOSARCOMA PATIENTS OVER AGE 60
Sasha Haarberg
Favorite
Haas, R.L.M.

Netherlands Cancer Institute
(P 24) NEOADJUVANT CHEMOTHERAPY FOR RADIOTHERAPY ASSOCIATED ANGIOSARCOMA (RAAS) OF THE BREAST IMPROVES ONCOLOGICAL OUTCOMES
R.L.M. Haas
Favorite
(P 194) EFFECTIVENESS OF A RISK PREDICTION TOOL (PERSARC) ON THE QUALITY OF TREATMENT DECISIONS IN SOFT-TISSUE SARCOMA PATIENTS (VALUE-PERSARC TRIAL)
R.L.M. Haas
Favorite
(P 317) SMARCB1-DEFICIENT SARCOMA OF THE GENITAL REGION/EPITHELIOID SARCOMA OF THE PROXIMAL TYPE VS EPITHELIOID SARCOMA OF THE DISTAL TYPE
R.L.M. Haas
Favorite
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
R.L.M. Haas
Favorite
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
R.L.M. Haas
Favorite
Haddox, Candace

Dana Farber Cancer Institute
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Candace Haddox
Favorite
(P 412) SARC044: A PHASE II TRIAL OF BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GIST WHO PROGRESSED ON SUNITINIB MONOTHERAPY
Candace Haddox
Favorite
Hadley, Abigail

University of Michigan
(P 423) COMPARISON OF CLINICAL COURSE AND FEATURES BETWEEN SCLEROSING EPITHELOID FIBROSARCOMA AND LOW-GRADE FIBROMYXOID SARCOMA
Abigail Hadley
Favorite
HAGIWARA, Yoko

Chiba Cancer center
(P 275) RECONSTRUCTION WITH A BURCH-SCHNEIDER CAGE AFTER BONE AND SOFT TISSUUE TUMOR SURGERY
Yoko HAGIWARA
Favorite
Haglund de Flon, Felix

Karolinska University Hospital
(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Felix Haglund de Flon
Favorite
(P 26) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Felix Haglund de Flon
Favorite
Haibe-Kains, Benjamin

Princess Margaret Cancer Centre, University Health Network
(P 399) SIMILARITY NETWORK FUSION IDENTIFIES DNA METHYLATION SUBTYPES OF LEIOMYOSARCOMA ASSOCIATED WITH CLINICAL OUTCOME
Benjamin Haibe-Kains
Favorite
(P 427) MULTI-OMIC AND MULTI-REGION PROFILING OF DESMOID TUMORS REVEALS INTRA- AND INTER-TUMOR HETEROGENEITY
Benjamin Haibe-Kains
Favorite
Hains, Peter

ProCan®, Children’s Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Peter Hains
Favorite
Hajdu, Katherine

Vanderbilt University Medical Center
(P 265) IS THERE AN IDEAL STEM TO CANAL RATIO IN LOWER EXTREMITY ONCOLOGIC ENDOPROSTHESIS RECONSTRUCTION?
Katherine Hajdu
Favorite
(P 404) ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL FOR PATENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITY: A PROSPECTIVE, NON-RANDOMIZED, CONSECUTIVELY ENROLLED TRIAL
Katherine Hajdu
Favorite
Hall, Frederick

Aveni Foundation
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Frederick Hall
Favorite
Hall, Timothy

University of Michigan
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Timothy Hall
Favorite
Halpern, Jennifer

Vanderbilt University Medical Center
(P 73) LONGER TIME INTERVAL BETWEEN NEOADJUVANT CHEMOTHERAPY AND SURGERY IS ASSOCIATED WITH DECREASED TUMOR PERCENT NECROSIS IN OSTEOSARCOMA
Jennifer Halpern
Favorite
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Jennifer Halpern
Favorite
(P 264) INTRAOPERATIVE FROZEN BONE MARROW MARGINS: A HELP OR A HINDRANCE IN EWING SARCOMA RESECTION?
Jennifer Halpern
Favorite
(P 265) IS THERE AN IDEAL STEM TO CANAL RATIO IN LOWER EXTREMITY ONCOLOGIC ENDOPROSTHESIS RECONSTRUCTION?
Jennifer Halpern
Favorite
(P 268) LOWER TUMOR PERCENT NECROSIS IS ASSOCIATED WITH POSITIVE FINAL SURGICAL MARGINS IN OSTEOSARCOMA
Jennifer Halpern
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Jennifer Halpern
Favorite
(P 404) ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL FOR PATENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITY: A PROSPECTIVE, NON-RANDOMIZED, CONSECUTIVELY ENROLLED TRIAL
Jennifer Halpern
Favorite
Hameed, Meera

Memorial Sloan Kettering Cancer Center
(P 380) MULTIDISCIPLINARY MANAGEMENT OF INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A 30-YEARS EXPERIENCE
Meera Hameed
Favorite
Hanada, Masuo

Kyushu Rosai Hospital
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Masuo Hanada
Favorite
Hanen, Simon

Portland Va Health Care System and OHSU Knight Cancer Institute
(P 173) IN VITRO PROFILING OF IDRX-42 AGAINST SECONDARY MUTATIONS FOUND IN TKI-RESISTANT GIST
Simon Hanen
Favorite
Hanff, David

Erasmus Medical Center
(P 154) PREOPERATIVE CLASSIFICATION OF NERVE SHEATH TUMORS USING RADIOMICS-BASED MACHINE LEARNING
David Hanff
Favorite
Hanif, Muhammad Rashid

SQCCCRC
(P 193) DISTRIBUTION OF CONNECTIVE TISSUE TUMORS BY HISTOLOGY AND DEGREE OF MALIGNANCY IN A SINGLE INSTITUTION IN OMAN
Muhammad Rashid Hanif
Favorite
Hanif, Rashid

SQCCCRC
(P 68) FEASIBILITY OF FIVE-DRUG INTERVAL-COMPRESSED CHEMOTHERAPY FOR ADOLESCENTS AND YOUNG ADULTS WITH EWING SARCOMA FAMILY TUMORS IN THE REAL-WORLD SETTING IN OMAN
Rashid Hanif
Favorite
Han, Ilkyu

Seoul National University Hospital
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Ilkyu Han
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Ilkyu Han
Favorite
(P 127) DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: A KOREAN MULTI-CENTER STUDY OF 107 CASES
Ilkyu Han
Favorite
(P 428) OLIGOMETASTASES IN EXTREMITY SOFT TISSUE SARCOMA : SUBTYPE-SPECIFIC ANALYSES OF CHARACTERISTICS AND OUTCOMES
Ilkyu Han
Favorite
Han, Jennifer

Boehringer Ingelheim Pharmaceuticals, Inc.
(P 133) REAL-WORLD ANALYSIS OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS) IN A US COMMUNITY ONCOLOGY SETTING
Jennifer Han
Favorite
(P 206) PATIENT PERSPECTIVE ON LIPOSARCOMA DIAGNOSTIC JOURNEY: INTERIM PATIENT SURVEY RESULTS
Jennifer Han
Favorite
Han, Jing

Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
Jing Han
Favorite
Hanna, Andrew

Memorial Sloan Kettering Cancer Center
(P 380) MULTIDISCIPLINARY MANAGEMENT OF INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A 30-YEARS EXPERIENCE
Andrew Hanna
Favorite
Hannah, Cathleen

Surgical Oncology Program, National Cancer Institute/National Institutes of Health
(P 163) CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS
Cathleen Hannah
Favorite
Hannour, Saloi

CENTRE LEON BERARD
(P 169) FRENCH LONG TERM REGISTRY WITH LONGITUDINAL FOLLOW UP OF PDGFRA D842V GIST PATIENTS (AVIATOR2020)
Saloi Hannour
Favorite
Han, Ruxu

Childrens Oncology Group
(P 50) ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Ruxu Han
Favorite
Hansén Nord, Karolin

Lund University
(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Karolin Hansén Nord
Favorite
(P 26) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Karolin Hansén Nord
Favorite
Hansen, Jolanta

Department of Oncology Medical Physics, Aarhus University Hospital
(P 357) RADIATION THERAPY OF EXTREMITY SOFT TISSUE SARCOMAS: A NATIONWIDE COHORT STUDY OF LATE SIDE EFFECTS - TRIAL IN PROGRESS
Jolanta Hansen
Favorite
Hansotia, Kyle

The Ohio State University College of Medicine
(P 244) PREDICTIVE VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN IMMUNOTHERAPY OUTCOMES IN ADVANCED SARCOMA
Kyle Hansotia
Favorite
Han, Yiqun

Mayo Clinic
(P 190) CLINICAL FEATURES ASSOCIATED WITH DIFFERENT HISTOLOGICAL SUBTYPES OF SARCOMA: A POPULATION-BASED STUDY OF 97062 CASES
Yiqun Han
Favorite
(P 210) RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST (RAASB): A NOMOGRAM FOR PREDICTING RECURRENCE AND PROGNOSIS
Yiqun Han
Favorite
Hao, Binbin

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
(P 93) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Binbin Hao
Favorite
Hao, Clara

Stanford University School of Medicine
(P 143) EARLY ASSESSMENT OF DISEASE RESPONSE TO IMMUNOTHERAPY VIA CIRCULATING TUMOR DNA IN ADVANCED SOFT TISSUE SARCOMAS
Clara Hao
Favorite
Haramiova, Zuzana

Thermosome GmbH
(P 410) PHASE I STUDY OF THE001 (DPPG2-TSL-DOX) COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Zuzana Haramiova
Favorite
Harley, Brendan

University of Illinois Urbana-Champaign
(P 419) BONE MECHANICS INFLUENCE CANCER STEM CELL FORMATION IN OSTEOSARCOMA
Brendan Harley
Favorite
Haro Varas, Juan Carlos

Instituto Nacional de Enfermedades Neoplasicas
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Juan Carlos Haro Varas
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Juan Carlos Haro Varas
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Juan Carlos Haro Varas
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Juan Carlos Haro Varas
Favorite
Haroun, Grace

Sarcoma Oncology Center
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Grace Haroun
Favorite
Harrow, Brooke

Deciphera Pharmaceuticals, LLC
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Brooke Harrow
Favorite
Hartner, Lee

Abramson Cancer Center
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
Lee Hartner
Favorite
Harvard, Hayden

Mercer University School of Medicine
(P 142) CORE NEEDLE BIOPSY OF PERIACETABULAR CHONDROSARCOMA OFTEN RESULTS IN UNDER-GRADING BUT DOES NOT CHANGE MANAGEMENT BY EXPERIENCED ORTHOPAEDIC ONCOLOGISTS.
Hayden Harvard
Favorite
Harwood, Catherine

Royal London Hospital
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Catherine Harwood
Favorite
Haskins, Kate

Roswell Park Comprehensive Cancer Center
(P 35) EARLY REAL WORLD EXPERIENCE WITH NIROGACESTAT IN PATIENTS WITH DESMOID FIBROMATOSIS
Kate Haskins
Favorite
Hastings, Reuben

NHS England, UCL Cancer Institute
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Reuben Hastings
Favorite
Haveman, Lianne

Princess Máxima Center for Pediatric Oncology
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Lianne Haveman
Favorite
Hawkins, Douglas

Seattle Children’s Hospital, University of Washington
(P 315) SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA
Douglas Hawkins
Favorite
Hayashi, Masanori

University of Colorado Cancer Center
(P 88) SPATIAL TRANSCRIPTOMICS OF EWING SARCOMA: EVOLUTION OF TUMOR MICROENVIRONMENT ASSOCIATED EXTRACELLULAR MATRIX FROM LOCALIZED TO METASTASIS-ASSOCIATED PRIMARY TUMORS
Masanori Hayashi
Favorite
Hayden, James

Oregon Health & Science University
(P 223) ASSOCIATION OF POSTOPERATIVE INFECTION (POI) WITH SOFT TISSUE SARCOMA (STS) RESECTION OUTCOMES
James Hayden
Favorite
(P 285) A NOVEL METHOD TO PREDICT HEIGHT AT SKELETAL MATURITY IN PEDIATRIC SARCOMA PATIENTS
James Hayden
Favorite
Heath, Emily

Cumming School of Medicine, University of Calgary
(P 174) INCIDENCE, TREATMENT PATTERNS, AND SURVIVAL OUTCOMES FOR ADULT PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) IN ALBERTA, CANADA FROM 2008 - 2022.
Emily Heath
Favorite
Heer, Collin

University of Iowa
(P 12) GENETIC LANDSCAPE OF MPNST DETERMINES METABOLIC STRATEGIES AND THERAPEUTIC OPPORTUNITIES FOR COPING WITH REDOX STRESS
Collin Heer
Favorite
Heeren, Amanda

Mayo Clinic
(P 200) FRAILTY ASSESSMENT IN OLDER PATIENTS RECEIVING SARCOMA THERAPY
Amanda Heeren
Favorite
Heesen, Philip

SwissSarcomaNetwork
(P 184) A SYSTEMATIC REVIEW ABOUT CLINICAL PROGNOSTIC MODELS FOR SARCOMAS
Philip Heesen
Favorite
(P 204) IMPACT OF UNPéLANNED EXCISION ON THE SURVIVAL OF SARCOMA PATIENTS - A TARGET TRIAL EMULATION
Philip Heesen
Favorite
Heiling, Hilary

Dana-Farber Cancer Institute
(P 107) DOES THE USE OF ADJUVANT CHEMOTHERAPY IN LOCALIZED, RESECTABLE SOFT TISSUE SARCOMA LEAD TO BETTER SURVIVAL OUTCOMES? - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Hilary Heiling
Favorite
Heilshorn, Sarah

Stanford University
(P 74) MATRIX DENSITY INDUCES CHEMORESISTANCE WITHIN A TISSUE-ENGINEERED MODEL OF OSTEOSARCOMA
Sarah Heilshorn
Favorite
Heimans, L

Netherlands Cancer Institute
(P 24) NEOADJUVANT CHEMOTHERAPY FOR RADIOTHERAPY ASSOCIATED ANGIOSARCOMA (RAAS) OF THE BREAST IMPROVES ONCOLOGICAL OUTCOMES
L Heimans
Favorite
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
L Heimans
Favorite
Heim, Tanya

University of Pittsburgh
(P 51) ASSESSING THE IN VIRTO EFFICACY OF DISULFIRAM AND ENZALUTAMIDE COMBINATION THERAPY IN METASTATIC OSTEOSARCOMA
Tanya Heim
Favorite
Heim, Tanya

UPMC Hillman Cancer Center
(P 240) INVESTIGATING MACROPHAGE POPULATION VARIABILITY IN METASTATIC SARCOMA SAMPLES
Tanya Heim
Favorite
(P 256) CHARACTERIZING ORTHOPAEDIC ONCOLOGIC POLYTRAUMAS: A COMPARISON OF PATIENTS UNDERGOING OPERATIVE FIXATION OF MULTIPLE LESIONS WITH THOSE WITH SOLITARY LESIONS
Tanya Heim
Favorite
(P 353) PREDICTING WOUND COMPLICATIONS FOLLOWING SOFT-TISSUE SARCOMA RESECTION AMONG PATIENTS WHO RECEIVED PRE-OPERATIVE RADIATION
Tanya Heim
Favorite
Heinrich, Michael

Portland VA Health Care System and OHSU Knight Cancer Institute
(P 173) IN VITRO PROFILING OF IDRX-42 AGAINST SECONDARY MUTATIONS FOUND IN TKI-RESISTANT GIST
Michael Heinrich
Favorite
(P 177) PREDICTING THE IMATINIB RESPONSE OF PDGFRA EXON 18-MUTANT GASTROINTESTINAL STROMAL TUMOR USING IN VITRO MODELS
Michael Heinrich
Favorite
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Michael Heinrich
Favorite
(P 227) EFFICACY OF IMMUNOTHERAPY IN TREATING METASTATIC MALIGNANT MYOPERICYTOMA: A CASE REPORT AND RIVEW OF LITERATURE
Michael Heinrich
Favorite
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Michael Heinrich
Favorite
(P 412) SARC044: A PHASE II TRIAL OF BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GIST WHO PROGRESSED ON SUNITINIB MONOTHERAPY
Michael Heinrich
Favorite
Heintz, Dimitri

Plant Imaging & Mass Spectrometry, PIMS- Institute of Plant Molecular Biology (IBMP), CNRS
(P 75) METABOLIC EVALUATION OF THE RELATIONSHIP BETWEEN MACROPHAGES AND OSTEOSARCOMA TUMOR CELLS
Dimitri Heintz
Favorite
Heise, Rachel

Weill Cornell Medicine
(P 102) ANALYSIS OF BLOOD-BASED BIOMARKERS AS PROGNOSTIC FACTORS IN PATIENTS WITH EHE TREATED WITH TRAMETINIB IN SARC033
Rachel Heise
Favorite
He, Kevin

Washington University in St. Louis
(P 145) EXPLORING L-TYPE AMINO ACID TRANSPORTER 1 (LAT1) AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Kevin He
Favorite
Helman, Lee

The Osteosarcoma Institute, Inc.
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Lee Helman
Favorite
Helmig, Sara

St. Jude Children’s Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Sara Helmig
Favorite
Hendrickson, Peter

Duke Univeristy
(P 301) GENOME-WIDE CRISPR/CAS9 VIABILITY SCREENS UNCOVER NOVEL GENETIC DEPENDENCIES IN CIC::DUX4 SARCOMA
Peter Hendrickson
Favorite
(P 303) INVESTIGATING THE THERAPEUTIC POTENTIAL OF TRIPTOLIDE PRODRUG, MINNELIDE, AS A TREATMENT ALTERNATIVE FOR CIC-DUX4 SARCOMA
Peter Hendrickson
Favorite
Henning, Jan-Willem

Tom Baker Cancer Center
(P 174) INCIDENCE, TREATMENT PATTERNS, AND SURVIVAL OUTCOMES FOR ADULT PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) IN ALBERTA, CANADA FROM 2008 - 2022.
Jan-Willem Henning
Favorite
Hensel, Jonathan

Moffitt Cancer Center
(P 237) INTRALESIONAL ADMINISTRATION OF TALIMOGENE LAHERPAREPVEC (T-VEC) INDUCES TUMOR REGRESSION IN PATIENTS WITH CUTANEOUS ANGIOSARCOMA
Jonathan Hensel
Favorite
Henshaw, Robert

Washington Hospital Center
(P 38) LOCAL RECURRENCE OF DIFFUSE PIGMENTED VILLONODULAR SYNOVITIS IN MAJOR JOINTS: A 15 YEAR-LONG CASE SERIES AT A SINGLE INSTITUTION
Robert Henshaw
Favorite
(P 39) PATIENT OUTCOMES FOLLOWING MINIMALLY INVASIVE TREATMENT OF ANEURYSMAL BONE CYSTS USING DOXYCYCLINE
Robert Henshaw
Favorite
(P 401) A PHASE 3 MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF EMACTUZUMAB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TANGENT)
Robert Henshaw
Favorite
(P 406) LONG-TERM DENOSUMAB THERAPY IN GIANT CELL TUMOR PATIENTS MAY POTENTIALLY LEAD TO THE DEVELOPMENT OF OTHER PRIMARY TUMORS: AN INITIAL OBSERVATION
Robert Henshaw
Favorite
Hensley, Martee

Memorial Sloan Kettering Cancer Center
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Martee Hensley
Favorite
Heredia Nieto, Omar

University of Miami/Jackson Health System
(P 314) RETROSPECTIVE EVALUATION OF DISPARITIES IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS WITH SYNOVIAL SARCOMA: A SINGLE INSTITUTION STUDY
Omar Heredia Nieto
Favorite
Hergenrother, Paul

University of Illinois Urbana-Champaign
(P 79) NOVEL THERAPEUTIC POTENTIAL THROUGH HYPERACTIVATION OF THE ANTICIPATORY UNFOLDED PROTEIN RESPONSE PATHWAY IN BONE CANCER TREATMENT
Paul Hergenrother
Favorite
Hermann, Frank

Thermosome GmbH
(P 410) PHASE I STUDY OF THE001 (DPPG2-TSL-DOX) COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Frank Hermann
Favorite
Hermoso, Luis

Complejo Hospitalario Universitario de Albacete
(P 432) THE ROLE OF SYSTEMIC TREATMENT IN ADVANCED SOLITARY FIBROUS TUMORS: EXPERIENCE AT A REFERRAL CENTER.
Luis Hermoso
Favorite
Herms, Lisa

Ontada
(P 133) REAL-WORLD ANALYSIS OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS) IN A US COMMUNITY ONCOLOGY SETTING
Lisa Herms
Favorite
Hernandez, Jonathan

Surgical Oncology Program, National Cancer Institute/National Institutes of Health
(P 163) CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS
Jonathan Hernandez
Favorite
(P 231) IDENTIFICATION OF NEOANTIGEN FROM PECOMA-LIKE NEOPLASM PROVIDES RATIONALE FOR TREATMENT WITH CELLULAR THERAPY
Jonathan Hernandez
Favorite
Hernando, Florentino

Hospital Clínico San Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Florentino Hernando
Favorite
Herrmann, Joerg

Mayo Clinic
(P 120) USING AI PREDICTIONS FROM ECG TRACINGS TO PREDICT TOLERANCE TO ANTHRACYCLINE CHEMOTHERAPY IN SARCOMA
Joerg Herrmann
Favorite
Hershenhouse, Tyler

Ann & Robert H Lurie Children's Hospital of Chicago
(P 04) CHROMOSOME SPECIFIC ORGANIZATIONAL CHARACTERISTICS IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS
Tyler Hershenhouse
Favorite
Hettmer, Simone

Faculty of Medicine at Martin Luther University Halle-Wittenberg (MLU)
(P 287) AN INTERNATIONAL SURVEY OF PROVIDER PRACTICES REGARDING BONE MARROW SAMPLING VERSUS [18F] FDG PET/CT IN THE DIAGNOSTIC EVALUATION OF BONE MARROW METASTASIS IN PEDIATRIC RHABDOMYOSARCOMA
Simone Hettmer
Favorite
Hiemcke-Jiwa, Laura

Princess Maxima Center for Pediatric Oncology, The Netherlands
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Laura Hiemcke-Jiwa
Favorite
Higazy, Randa

University Health Network
(P 433) TUMOR HYPOXIA AND THE RISK OF METASTASIS IN HIGH-RISK LOCALIZED UPS/MFS
Randa Higazy
Favorite
Hikmet, Ramsen

Department of Oncology, Aarhus University Hospital.
(P 357) RADIATION THERAPY OF EXTREMITY SOFT TISSUE SARCOMAS: A NATIONWIDE COHORT STUDY OF LATE SIDE EFFECTS - TRIAL IN PROGRESS
Ramsen Hikmet
Favorite
Hildebrand, Karys

University of Calgary
(P 236) INTERFERON STIMULATED GENE SCORES ARE ELEVATED IN THE MYELOID COMPARTMENT OF MURINE KP UNDIFFERENTIATED PLEOMORPHIC TUMORS TREATED WITH TRANSLATIONAL STING AGONISTS
Karys Hildebrand
Favorite
(P 239) INVESTIGATING HOW TUMOUR ASSOCIATED MACROPHAGES INFLUENCE THE EFFICACY OF CAR T THERAPY IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Karys Hildebrand
Favorite
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
Karys Hildebrand
Favorite
(P 333) ESTIMATING IMMUNE INFILTRATES OF NOVEL GENETICALLY ENGINEERED MOUSE MODELS OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Karys Hildebrand
Favorite
Hildebrand, Kurt

University of Calgary
(P 236) INTERFERON STIMULATED GENE SCORES ARE ELEVATED IN THE MYELOID COMPARTMENT OF MURINE KP UNDIFFERENTIATED PLEOMORPHIC TUMORS TREATED WITH TRANSLATIONAL STING AGONISTS
Kurt Hildebrand
Favorite
(P 239) INVESTIGATING HOW TUMOUR ASSOCIATED MACROPHAGES INFLUENCE THE EFFICACY OF CAR T THERAPY IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Kurt Hildebrand
Favorite
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
Kurt Hildebrand
Favorite
(P 333) ESTIMATING IMMUNE INFILTRATES OF NOVEL GENETICALLY ENGINEERED MOUSE MODELS OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Kurt Hildebrand
Favorite
Hindi, Nadia

Fundacion Jimenez Diaz University Hospital
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Nadia Hindi
Favorite
Hiniker, Susan

Stanford University
(P 356) RADIATION PRACTICE PATTERNS AND OUTCOMES IN ADOLESCENT YOUNG ADULT PATIENTS WITH VISCERAL NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Susan Hiniker
Favorite
Hirai, Toshihide

National Cancer Center Institute
(P 103) BRAF MUTATIONS AND CONCURRENT ALTERATIONS IN PATIENTS WITH SOFT TISSUE SARCOMA
Toshihide Hirai
Favorite
Hirbe, Angela

Washington University in St. Louis School of Medicine, Division of Oncology
(P 10) GENERATION OF A CHROMOSOME 8 GAIN;NF1-/- HUMAN INDUCED PLURIPOTENT STEM CELL DERIVED SCHWANN CELL PRECURSOR MODEL
Angela Hirbe
Favorite
(P 145) EXPLORING L-TYPE AMINO ACID TRANSPORTER 1 (LAT1) AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Angela Hirbe
Favorite
(P 149) LACK OF CORRELATION OF FDG-PET/CT SUV MAXIMUM AND MALIGNANT TRANSFORMATION IN NEUROFIBROMATOSIS TYPE 1-RELATED PLEXIFORM NEUROFIBROMAS
Angela Hirbe
Favorite
(P 187) BRIDGING THE GAP: UNDERSTANDING THE CURRENT TREATMENT RESPONSES TO ENHANCE THE STANDARD OF CARE AND OUTCOMES FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Angela Hirbe
Favorite
(P 335) FOCAL ADHESION KINASE (FAK) IS A THERPEUTIC TARGET IN CHROMOSOME 8 GAIN-ASSOCIATED MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Angela Hirbe
Favorite
Hirose, Takeshi

Memorial Sloan Kettering Cancer Center
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Takeshi Hirose
Favorite
Hirozane, Toru

Department of Orthopaedic Surgery, Kyorin University Faculty of Medicine
(P 18) IMMUNOHISTOCHEMICAL ANALYSIS OF NUCLEAR β-CATENIN IN BONE AND SOFT TISSUE TUMOR MICROARRAYS
Toru Hirozane
Favorite
HOANG, BANG

Montefiore Medical Center
(P 59) COMPREHENSIVE SINGLE CELL TRANSCRIPTOMICS ANALYSIS OF MURINE OSTEOSARCOMA UNCOVERS SKP2 FUNCTION IN METASTASIS, GENOMIC INSTABILITY AND IMMUNE ACTIVATION AND REALS ADDITIONAL TARGET PATHWAYS
BANG HOANG
Favorite
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
BANG HOANG
Favorite
(P 156) PROFILING SYNOVIAL SARCOMA EXTRACELLULAR VESICLES FOR DIAGNOSTIC RNA BIOMARKERS
BANG HOANG
Favorite
Hobson, Jared

Mayo Clinic
(P 210) RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST (RAASB): A NOMOGRAM FOR PREDICTING RECURRENCE AND PROGNOSIS
Jared Hobson
Favorite
Hodo, Thomas

Massachusetts General Hospital
(P 108) FIXATION OF IMPENDING OR PATHOLOGIC FRACTURES DUE TO METASTATIC DISEASE WITH CARBON FIBER INTRAMEDULLARY NAILS-A PROPENSITY-SCORE MATCHED COST ANALYSIS
Thomas Hodo
Favorite
Hohenberger, Peter

Div.of Surgical Oncology and Thoracic surgery, Mannheim University Medical Center, University of Heidelberg, Germany
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Peter Hohenberger
Favorite
Hojo, Hidehiro

National Cancer Center Hospital East
(P 354) PROTON BEAM THERAPY FOR PEDIATRIC AND ADOLESCENT SARCOMA FROM OVERSEAS
Hidehiro Hojo
Favorite
Holloway, Caroline

BC Cancer
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Caroline Holloway
Favorite
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Caroline Holloway
Favorite
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Caroline Holloway
Favorite
Holt, Ginger

Vanderbilt University Medical Center
(P 73) LONGER TIME INTERVAL BETWEEN NEOADJUVANT CHEMOTHERAPY AND SURGERY IS ASSOCIATED WITH DECREASED TUMOR PERCENT NECROSIS IN OSTEOSARCOMA
Ginger Holt
Favorite
(P 265) IS THERE AN IDEAL STEM TO CANAL RATIO IN LOWER EXTREMITY ONCOLOGIC ENDOPROSTHESIS RECONSTRUCTION?
Ginger Holt
Favorite
(P 268) LOWER TUMOR PERCENT NECROSIS IS ASSOCIATED WITH POSITIVE FINAL SURGICAL MARGINS IN OSTEOSARCOMA
Ginger Holt
Favorite
(P 404) ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL FOR PATENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITY: A PROSPECTIVE, NON-RANDOMIZED, CONSECUTIVELY ENROLLED TRIAL
Ginger Holt
Favorite
Hompes, Daphne

University Hospitals Gasthuisberg Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Daphne Hompes
Favorite
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Daphne Hompes
Favorite
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Daphne Hompes
Favorite
Hompland, Ivar

Oslo University Hospital
(P 40) PEGYLATED LIPOSOMAL DOXORUBICIN IN SYMPTOMATIC DESMOID TUMOR
Ivar Hompland
Favorite
Hompland, Tord

Oslo University Hospital
(P 40) PEGYLATED LIPOSOMAL DOXORUBICIN IN SYMPTOMATIC DESMOID TUMOR
Tord Hompland
Favorite
Hong, Angela

Royal Prince Alfred Hospital
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Angela Hong
Favorite
Hong, David

The University of Texas MD Anderson Cancer Center
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
David Hong
Favorite
(P 396) LONG-TERM FOLLOW-UP EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
David Hong
Favorite
Honoki, Kanya

Nara Medical University
(P 85) PTEROSTILBENE SENSITIZES OSTEOSARCOMA CELLS TO KILLING BY C-MYC INHIBITORS
Kanya Honoki
Favorite
(P 313) RELATION BETWEEN NUTRITIONAL/INFLAMMATORY PARAMETERS AND PROGNOSIS IN CHILDHOOD SARCOMA PATIENTS
Kanya Honoki
Favorite
Honore, Lesly

Rush University Medical Center
(P 31) CLINICAL CHALLENGES AND EVOLVING TREATMENT STRATEGIES IN DESMOID FIBROMATOSIS: A SINGLE INSTITUTION EXPERIENCE
Lesly Honore
Favorite
(P 126) CHARACTERIZING THE TRANSFORMATION AND DIAGNOSIS OF ATYPICAL LIPOMATOUS TUMOR OF THE EXTREMITIES TO DEDIFFERENTIATED LIPOSARCOMA: SINGLE INSTITUTIONAL OUTCOMES
Lesly Honore
Favorite
Hopyan, Sevan

Hospital for Sick Children and University of Toronto
(P 304) LOCAL CONTROL FOR PEDIATRIC RHABDOMYOSARCOMA OF THE EXTREMITIES. IS RADIOTHERAPY ALWAYS REQUIRED AFTER ADEQUATE SURGICAL RESECTION?
Sevan Hopyan
Favorite
Horgan, Santiago

University of California, San Diego
(P 167) DEFINING TEXTBOOK OUTCOMES FOR MINIMALLY INVASIVE SURGICAL RESECTION OF SMALL GASTROINTESTINAL STROMAL TUMORS (GIST) OF THE STOMACH
Santiago Horgan
Favorite
Hornicek, Francis

University of Miami
(P 58) COMBINATORY THERAPIES UTILIZING INHIBITION OF CARBONIC ANHYDRASE IX TO POTENTIATE RESPONSE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Francis Hornicek
Favorite
(P 346) BRACHYTHERAPY FOR SOFT TISSUE SARCOMA: MAINTAINING LOCAL CONTROL WHILE MINIMIZING COMPLICATIONS
Francis Hornicek
Favorite
Horonjeff, Jen

Savvy Cooperative
(P 206) PATIENT PERSPECTIVE ON LIPOSARCOMA DIAGNOSTIC JOURNEY: INTERIM PATIENT SURVEY RESULTS
Jen Horonjeff
Favorite
Horvath, Lisa

Chris O'Brien Lifehouse
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Lisa Horvath
Favorite
Hoskin, Tyler

Atlantic Health System
(P 405) LIPOSOMAL BUPIVACAINE DOESN'T REDUCE NARCOTIC USE OR PAIN SCORES COMPARED TO A MULTIDRUG COCKTAIL FOLLOWING SOFT TISSUE TUMOR REMOVAL: PRELIM RESULTS OF A PROSPECTIVE, RANDOMIZED DOUBLE-BLINDED STUDY
Tyler Hoskin
Favorite
Hosogane, Naobumi

Kyorin University
(P 18) IMMUNOHISTOCHEMICAL ANALYSIS OF NUCLEAR β-CATENIN IN BONE AND SOFT TISSUE TUMOR MICROARRAYS
Naobumi Hosogane
Favorite
Hosono, AKO

National Cancer Center Hospital East
(P 354) PROTON BEAM THERAPY FOR PEDIATRIC AND ADOLESCENT SARCOMA FROM OVERSEAS
AKO Hosono
Favorite
Hosseini, Mojgan

University of California San Diego
(P 175) KIT AND DOG-1 EXPRESSING GASTROINTESTINAL STROMAL TUMORS HARBORING ETV6-NTRK3 FUSIONS DO EXIST, CASE OF NEAR COMPLETE PATHOLOGIC RESPONSE FOLLOWING LAROTRECTINIB AND REVIEW OF THE LITERATURE
Mojgan Hosseini
Favorite
Ho, Thanh

Mayo Clinic
(P 120) USING AI PREDICTIONS FROM ECG TRACINGS TO PREDICT TOLERANCE TO ANTHRACYCLINE CHEMOTHERAPY IN SARCOMA
Thanh Ho
Favorite
(P 200) FRAILTY ASSESSMENT IN OLDER PATIENTS RECEIVING SARCOMA THERAPY
Thanh Ho
Favorite
Houdek, Matthew

Mayo Clinic
(P 210) RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST (RAASB): A NOMOGRAM FOR PREDICTING RECURRENCE AND PROGNOSIS
Matthew Houdek
Favorite
(P 267) LONG-TERM FUNCTIONAL OUTCOMES OF SHOULDER ARTHRODESIS FOR TUMOR RESECTION
Matthew Houdek
Favorite
(P 278) ROTATIONPLASTY AS AN EFFECTIVE LIMB SALVAGE OPTION IN THE ADULT POPULATION
Matthew Houdek
Favorite
(P 294) COMPARING HIGH-GRADE NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA IN ADULT AND PEDIATRIC POPULATIONS
Matthew Houdek
Favorite
(P 307) OUTCOMES OF PEDIATRIC NON-RHABDOMYOSARCOMA SOFT-TISSUE SARCOMAS OF THE EXTREMITIES
Matthew Houdek
Favorite
Hounschell, Corey

University of Kansas, Department of Surgery
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Corey Hounschell
Favorite
house, Michael

Indiana University School of Medicine
(P 384) REAL WORLD EXPERIENCE IN TREATING HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: AN ULTRA-RARE VASCULAR TUMOR
Michael house
Favorite
Hsu, Che-Yu

National Taiwan University Hospital
(P 348) EVALUATING THE IMPACT OF BIOLOGICAL EFFECTIVE DOSE AND DELAYED RADIOTHERAPY ON THE SYNERGISTIC EFFICACY OF TRABECTEDIN IN METASTATIC SOFT TISSUE SARCOMA PATIENTS
Che-Yu Hsu
Favorite
Huang, Elise

University of California Santa Cruz, Molecular Cell and Developmental Biology, Genomics Institute
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
Elise Huang
Favorite
(P 156) PROFILING SYNOVIAL SARCOMA EXTRACELLULAR VESICLES FOR DIAGNOSTIC RNA BIOMARKERS
Elise Huang
Favorite
Huang, Karen

Children's Hospital of Philadelphia
(P 318) SYNOVIAL SARCOMA REGISTRY AND BIOSPECIMEN REPOSITORY: DESCRIBING THE COHORT AND SURVIVAL OUTCOMES TO DATE
Karen Huang
Favorite
Huang, Michelle

Stanford University
(P 74) MATRIX DENSITY INDUCES CHEMORESISTANCE WITHIN A TISSUE-ENGINEERED MODEL OF OSTEOSARCOMA
Michelle Huang
Favorite
Huang, Paul

ICR
(P 17) IDENTIFICATION OF MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL IN LEIOMYOSARCOMA THROUGH MIRNA SEQUENCING
Paul Huang
Favorite
Huang, Rui

Beckman Research Institute at City of Hope
(P 07) DIRECTLY TARGETING CIC-DUX4 FUSION AND MYC ONCOPROTEINS FOR UNDIFFERENTIATED ROUND CELL SARCOMAS
Rui Huang
Favorite
Huang, Wei

OHSU
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Wei Huang
Favorite
Huang, Wenjun

Seattle Children's Research Institute
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Wenjun Huang
Favorite
Hua, Yingqi

Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
Yingqi Hua
Favorite
(P 83) PREDICTION OF HIGH-RISK OSTEOSARCOMA PATIENTS BASED ON MACHINE LEARNING USING TRANSCRIPTOME AND METHYLATION DATA FROM SGH-COHORT
Yingqi Hua
Favorite
(P 90) TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL
Yingqi Hua
Favorite
(P 93) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Yingqi Hua
Favorite
Hubbard, Ryan

University of Michigan
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Ryan Hubbard
Favorite
Hubsch, Clémence

UMR7021 CNRS -Laboratory of Bioimaging and Pathologies
(P 75) METABOLIC EVALUATION OF THE RELATIONSHIP BETWEEN MACROPHAGES AND OSTEOSARCOMA TUMOR CELLS
Clémence Hubsch
Favorite
(P 89) TARGETED THERAPY OF MET, TYROSINE KINASE RECEPTOR, IN PEDIATRIC HIGH-GRADE OSTEOSARCOMAS : A NEW WAY TO TREAT PATIENTS ?
Clémence Hubsch
Favorite
(P 426) GD2 HETEROGENEIC EXPRESSION IN OSTEOSARCOMAS AND EWING SARCOMAS UNDERLYING A WORST PROGNOSIS
Clémence Hubsch
Favorite
Huerta-Lopez, Carla

Stanford University
(P 74) MATRIX DENSITY INDUCES CHEMORESISTANCE WITHIN A TISSUE-ENGINEERED MODEL OF OSTEOSARCOMA
Carla Huerta-Lopez
Favorite
Hui, Gavin

Atropos Health
(P 209) RACE AND ETHNICITY ON DIAGNOSIS, METASTASIS, AND MORTALITY OF SOFT TISSUE SARCOMAS IN RETROSPECTIVE COHORT STUDY
Gavin Hui
Favorite
Hu, James

University of Southern California, Norris Comprehensive Cancer Center
(P 158) RECURRENT RADIATION-INDUCED SARCOMA IN A PATIENT WITH HEREDITARY RETINOBLASTOMA: PRESENTATION AND OUTCOME
James Hu
Favorite
Hu, James

University of Southern California Norris Comprehensive Cancer Center
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
James Hu
Favorite
Hung, Arthur

Oregon Health & Science University
(P 359) RAPIDLY PROGRESSIVE, NON-METASTATIC, CUTANEOUS ANGIOSARCOMA OF FACE AND SCALP TREATED WITH HYPOFRACTIONATED RADIATION THERAPY: A CASE SERIES
Arthur Hung
Favorite
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Arthur Hung
Favorite
Hung, Yin

Massachusetts General Hospital
(P 63) DOES TUMOR NECROSIS IMPACT PROGNOSIS IN CHONDROBLASTIC AND OSTEOBLASTIC OSTEOSARCOMA? A STUDY FROM A LARGE TERTIARY CARE ACADEMIC CENTER
Yin Hung
Favorite
Hunt, Kelly

MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Kelly Hunt
Favorite
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Kelly Hunt
Favorite
Hurley, Rachel

Children's Hospital of Philadelphia
(P 318) SYNOVIAL SARCOMA REGISTRY AND BIOSPECIMEN REPOSITORY: DESCRIBING THE COHORT AND SURVIVAL OUTCOMES TO DATE
Rachel Hurley
Favorite
Hurtt, Jo

National Cancer Institute
(P 414) TENOSYNOVIAL GIANT CELL TUMOR IN CHILDREN: INTERIM RESULTS FROM A PHASE 1 STUDY OF TURALIO®
Jo Hurtt
Favorite
Husain, Marium

The Ohio State University
(P 207) PATIENT-REPORTED GLOBAL HEALTH PREDICTS ADVERSE HEALTH OUTCOMES IN PATIENTS WITH ADVANCED SARCOMA
Marium Husain
Favorite
(P 244) PREDICTIVE VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN IMMUNOTHERAPY OUTCOMES IN ADVANCED SARCOMA
Marium Husain
Favorite
(P 328) DETERMINING BIOMARKERS FOR GEMCITABINE RESPONSE IN SOFT TISSUE SARCOMAS: LESSONS LEARNED FROM PANCREATIC CANCER
Marium Husain
Favorite
Hussain, Ahmed

The Ohio State University James Comprehensive Cancer Center
(P 207) PATIENT-REPORTED GLOBAL HEALTH PREDICTS ADVERSE HEALTH OUTCOMES IN PATIENTS WITH ADVANCED SARCOMA
Ahmed Hussain
Favorite
Huynh, Thien Huong

University of South Florida Morsani College of Medicine
(P 257) COMPARATIVE OUTCOMES OF CONSTRAINED ACETABULAR LINERS VS. DUAL MOBILITY CUPS IN COMPLEX HIP RECONSTURCTION FOR METASTATIC BONE DISEASE
Thien Huong Huynh
Favorite
(P 262) EVALUATION OF STAGED RESECTION WITH TEMPORIZING VAC OF SOFT TISSUE SARCOMAS
Thien Huong Huynh
Favorite
(P 279) SIGNIFICANCE OF TIP-APEX DISTANCE IN ACTUAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
Thien Huong Huynh
Favorite
Hyder Junejo, Muhammad

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Muhammad Hyder Junejo
Favorite